These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36900367)

  • 21. Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
    Lindley A; Prager G; Bitzer M; Burn TC; Lihou CF; Croft E
    Cancer Res Treat; 2024 Jul; 56(3):847-855. PubMed ID: 38351684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.
    Gilbert TM; Randle L; Quinn M; McGreevy O; O'leary L; Young R; Diaz-Neito R; Jones RP; Greenhalf B; Goldring C; Fenwick S; Malik H; Palmer DH
    Eur J Surg Oncol; 2024 Apr; ():108352. PubMed ID: 38653586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
    Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.
    Valery M; Vasseur D; Fachinetti F; Boilève A; Smolenschi C; Tarabay A; Antoun L; Perret A; Fuerea A; Pudlarz T; Boige V; Hollebecque A; Ducreux M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision Oncology Targets in Biliary Tract Cancer.
    Farha N; Dima D; Ullah F; Kamath S
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
    Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
    World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary's Pioneering Research.
    Cortiana V; Chorya H; Joshi M; Kannan S; Mahendru D; Vallabhaneni H; Coloma HS; Leyfman Y; Park CH
    Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic treatment options for advanced biliary tract carcinoma.
    Xie C; McGrath NA; Monge Bonilla C; Fu J
    J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
    Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
    BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
    Vogel A; Sahai V; Hollebecque A; Vaccaro GM; Melisi D; Al Rajabi RM; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Lihou CF; Zhen H; Veronese ML; Abou-Alfa GK
    ESMO Open; 2024 Jun; 9(6):103488. PubMed ID: 38838500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
    Neumann O; Burn TC; Allgäuer M; Ball M; Kirchner M; Albrecht T; Volckmar AL; Beck S; Endris V; Goldschmid H; Lehmann U; Seker-Cin H; Uhrig S; Roessler S; Budczies J; Fröhling S; Longerich T; Wagner AH; Vogel A; Schirmacher P; Stenzinger A; Kazdal D
    Br J Cancer; 2022 Nov; 127(8):1540-1549. PubMed ID: 35871236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.